Wind Advisory
from SAT 12:00 PM MST until SAT 10:00 PM MST, Western Pima County including Ajo/Organ Pipe Cactus National Monument, Tohono O'odham Nation including Sells, Upper Santa Cruz River and Altar Valleys including Nogales, Tucson Metro Area including Tucson/Green Valley/Marana/Vail, South Central Pinal County including Eloy/Picacho Peak State Park, Southeast Pinal County including Kearny/Mammoth/Oracle, Upper San Pedro River Valley including Sierra Vista/Benson, Eastern Cochise County below 5000 ft including Douglas/Wilcox, Upper Gila River and Aravaipa Valleys including Clifton/Safford, White Mountains of Graham and Greenlee Counties including Hannagan Meadow, Galiuro and Pinaleno Mountains including Mount Graham, Chiricahua Mountains including Chiricahua National Monument, Dragoon/Mule/Huachuca and Santa Rita Mountains including Bisbee/Canelo Hills/Madera Canyon, Santa Catalina and Rincon Mountains including Mount Lemmon/Summerhaven, Baboquivari Mountains including Kitt Peak, Kofa, Central La Paz, Aguila Valley, Southeast Yuma County, Gila River Valley, Northwest Valley, Tonopah Desert, Gila Bend, Buckeye/Avondale, Cave Creek/New River, Deer Valley, Central Phoenix, North Phoenix/Glendale, New River Mesa, Scottsdale/Paradise Valley, Rio Verde/Salt River, East Valley, Fountain Hills/East Mesa, South Mountain/Ahwatukee, Southeast Valley/Queen Creek, Superior, Northwest Pinal County, West Pinal County, Apache Junction/Gold Canyon, Tonto Basin, Mazatzal Mountains, Pinal/Superstition Mountains, Sonoran Desert Natl Monument, San Carlos, Dripping Springs, Globe/Miami, Southeast Gila County

Baylor Scott & White releases results of study on the use of Remdesivir to treat COVID-19 patients

Baylor Scott & White is reporting some good news about treatment for COVID-19 patients.

The hospital released some results of a study on the use of Remdesivir.

Baylor Scott & White Health is one of 180 hospitals participating in a worldwide Gilead Sciences study of its antiviral drug Remdesivir to treat people who are severely hospitalized with COVID-19.

MORE: Coronavirus coverage

P_ALLISON REMDESIVIR METHODIST TRIALS 9P_00.00.53.11

“What’s a patient come to a hospital for? They want to live longer, they want to live better, and they want to get better,” said Dr. Robert Gottlieb, who is a cardiologist at Baylor Scott & White.

And hospital officials said the results show Remdesivir is doing just that, consistently shortening recovery time and saving lives.

“And now we have shown that there’s a very strong suggestion of survival benefit,” Gottlieb said. “And that Remdesivir decreased your odds of passing away from COVID-19 by about 62 percent.”

Dr. Gottlieb said Remdesivir is challenging to make, there’s a limited supply, and it takes time to ramp up production.

It’s not the best of news during a pandemic, but he added that studies show patients need only half the dose of what was originally thought.

“Does five days of Remdesivir verses 10 days of Remdesivir make a difference or are they both helpful?” Dr. Gottlieb said. “We showed that five days was as good as 10 days.”

Which means you can treat nearly twice as many patients with the same supply.

The study did not take into account patients on breathing tubes or ventilators, but Baylor officials said the findings certainly provide hope.

“Because now we know that we have therapies that we can offer that can help our patients,” Dr. Gottlieb added.

RELATED: Interactive map of Texas COVID-19 cases